OncoMatch/Clinical Trials/NCT06298955
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
Is NCT06298955 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies OMS906 study drug for paroxysmal nocturnal hemoglobinuria.
Treatment: OMS906 study drug — The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: (OMS906) — prior OMS906 PNH study
Have completed the last dosing visit of the prior OMS906 PNH study.
Lab requirements
Blood counts
platelet count ≥ 30,000/µL, absolute neutrophil count ≥ 500 cells/µL at the start of the Evaluation Period
Liver function
total bilirubin ≤ 2 x ULN, direct bilirubin ≤ 1.5 x ULN, transaminases (ALT/AST) ≤ 2 x ULN unless due to PNH-related hemolysis
Platelet count <30,000/µL or absolute neutrophil count <500 cells/µL at the start of the Evaluation Period. Elevation of liver function tests, defined as total bilirubin > 2 x ULN, direct bilirubin > 1.5 x ULN, and elevated transaminases (alanine or aspartate aminotransferase), > 2 X ULN unless due to PNH-related hemolysis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06298955 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received .
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify